WO2004010974A3 - Capsule de gelatine a reticulation reduite - Google Patents

Capsule de gelatine a reticulation reduite Download PDF

Info

Publication number
WO2004010974A3
WO2004010974A3 PCT/US2003/024045 US0324045W WO2004010974A3 WO 2004010974 A3 WO2004010974 A3 WO 2004010974A3 US 0324045 W US0324045 W US 0324045W WO 2004010974 A3 WO2004010974 A3 WO 2004010974A3
Authority
WO
WIPO (PCT)
Prior art keywords
linking
reduced cross
exhibiting reduced
gelatin capsule
capsule exhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/024045
Other languages
English (en)
Other versions
WO2004010974A2 (fr
Inventor
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to MXPA05001167A priority Critical patent/MXPA05001167A/es
Priority to AU2003257103A priority patent/AU2003257103A1/en
Priority to JP2004524263A priority patent/JP2005538102A/ja
Priority to EP03772161A priority patent/EP1526846A2/fr
Priority to CA002493980A priority patent/CA2493980A1/fr
Priority to BR0313150-5A priority patent/BR0313150A/pt
Publication of WO2004010974A2 publication Critical patent/WO2004010974A2/fr
Publication of WO2004010974A3 publication Critical patent/WO2004010974A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)

Abstract

L'invention concerne des compositions destinées à être utilisées pour la préparation de capsules de gélatine. Elle concerne également des capsules de gélatine présentant une réticulation réduite, ainsi que des procédés de préparation de telles capsules de gélatine..
PCT/US2003/024045 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite Ceased WO2004010974A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA05001167A MXPA05001167A (es) 2002-07-31 2003-07-31 Capsula de gelatina que exhibe reticulacion reducida.
AU2003257103A AU2003257103A1 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking
JP2004524263A JP2005538102A (ja) 2002-07-31 2003-07-31 低下された架橋を示すゼラチンカプセル
EP03772161A EP1526846A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
CA002493980A CA2493980A1 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
BR0313150-5A BR0313150A (pt) 2002-07-31 2003-07-31 Cápsulas de gelatina que exibem ligação reticulada reduzida

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US39986302P 2002-07-31 2002-07-31
US39980802P 2002-07-31 2002-07-31
US39986202P 2002-07-31 2002-07-31
US39977602P 2002-07-31 2002-07-31
US60/399,776 2002-07-31
US60/399,862 2002-07-31
US60/399,808 2002-07-31
US60/399,863 2002-07-31

Publications (2)

Publication Number Publication Date
WO2004010974A2 WO2004010974A2 (fr) 2004-02-05
WO2004010974A3 true WO2004010974A3 (fr) 2004-08-05

Family

ID=31192378

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/024045 Ceased WO2004010974A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
PCT/US2003/024044 Ceased WO2004022032A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite
PCT/US2003/024043 Ceased WO2004010973A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique conservant un profil de dissolution stable au stockage
PCT/US2003/024042 Ceased WO2004010972A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules

Family Applications After (3)

Application Number Title Priority Date Filing Date
PCT/US2003/024044 Ceased WO2004022032A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite
PCT/US2003/024043 Ceased WO2004010973A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique conservant un profil de dissolution stable au stockage
PCT/US2003/024042 Ceased WO2004010972A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules

Country Status (7)

Country Link
EP (4) EP1526846A2 (fr)
JP (4) JP2005538994A (fr)
AU (4) AU2003257982A1 (fr)
BR (4) BR0313150A (fr)
CA (4) CA2493980A1 (fr)
MX (4) MXPA05000862A (fr)
WO (4) WO2004010974A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524000T3 (es) 2002-06-05 2014-12-03 Teva Czech Industries S.R.O. Reducción de la reticulación de la gelatina
MX2007009888A (es) 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
AU2006274098B2 (en) 2005-07-26 2012-02-09 Nicox Science Ireland Pharmaceutical formulation of nitrooxyderivatives of NSAIDs
JP5503939B2 (ja) * 2009-10-16 2014-05-28 東洋カプセル株式会社 アゼラスチン塩酸塩含有カプセル剤
JP6887456B2 (ja) 2018-07-04 2021-06-16 キャプシュゲル・ベルジウム・エヌ・ヴィ 白色化剤として界面活性剤又は界面活性剤と塩を含有する皮膜形成性組成物
US11364478B2 (en) * 2019-05-22 2022-06-21 Mezzimatic, LLC Method of manufacturing throwable paintballs and paintballs made therefrom
PE20240222A1 (es) * 2020-12-01 2024-02-16 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
CN113230241A (zh) * 2021-06-11 2021-08-10 北京畅盛医药科技有限公司 三羟甲基氨基甲烷盐在治疗心脑血管病的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204401A1 (fr) * 1972-11-01 1974-05-24 Meiji Seika Co
GB2073589A (en) * 1980-04-14 1981-10-21 Squibb & Sons Inc Diagnostic and therapeutic radio pharmaceutical capsules
FR2617047A1 (fr) * 1987-06-23 1988-12-30 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
EP0695544A1 (fr) * 1994-08-05 1996-02-07 Shionogi & Co., Ltd. Capsules en gélatine dure résistantes à la dénaturation et procédé de leur préparation
WO1996014365A2 (fr) * 1994-11-07 1996-05-17 Warner-Lambert Company Procede de stabilisation de produits gelatineux

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP2790659B2 (ja) * 1989-06-30 1998-08-27 帝国臓器製薬株式会社 ゼラチンカプセル剤
EP1163906A3 (fr) * 1994-03-15 2003-05-21 Senju Pharmaceutical Co., Ltd. Méthode pour la stabilisation du pranoprofène et composition stable liquide contenant du pranoprofène
IT1269583B (it) * 1994-04-26 1997-04-08 Bayer Italia Spa Preparazioni farmaceutiche a base di una soluzione di ketoprofene in capsule di gelatina molle e metodo per la loro produzione
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2204401A1 (fr) * 1972-11-01 1974-05-24 Meiji Seika Co
GB2073589A (en) * 1980-04-14 1981-10-21 Squibb & Sons Inc Diagnostic and therapeutic radio pharmaceutical capsules
FR2617047A1 (fr) * 1987-06-23 1988-12-30 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
EP0695544A1 (fr) * 1994-08-05 1996-02-07 Shionogi & Co., Ltd. Capsules en gélatine dure résistantes à la dénaturation et procédé de leur préparation
WO1996014365A2 (fr) * 1994-11-07 1996-05-17 Warner-Lambert Company Procede de stabilisation de produits gelatineux

Also Published As

Publication number Publication date
WO2004010972A3 (fr) 2004-07-29
JP2005538993A (ja) 2005-12-22
AU2003257981A8 (en) 2004-02-16
JP2005538994A (ja) 2005-12-22
AU2003257982A8 (en) 2004-02-16
AU2003257103A1 (en) 2004-02-16
WO2004022032A2 (fr) 2004-03-18
AU2003257103A8 (en) 2004-02-16
AU2003257102A1 (en) 2004-03-29
BR0312875A (pt) 2005-06-28
MXPA05000862A (es) 2005-04-19
CA2494069A1 (fr) 2004-02-05
WO2004010972A2 (fr) 2004-02-05
CA2494358A1 (fr) 2004-02-05
EP1526844A2 (fr) 2005-05-04
WO2004010973A3 (fr) 2004-08-05
BR0313150A (pt) 2005-06-28
CA2493980A1 (fr) 2004-02-05
BR0313149A (pt) 2005-06-28
WO2004010973A2 (fr) 2004-02-05
MXPA05001272A (es) 2005-04-28
EP1526847A2 (fr) 2005-05-04
AU2003257981A1 (en) 2004-02-16
CA2493974A1 (fr) 2004-03-18
JP2006500389A (ja) 2006-01-05
WO2004022032A3 (fr) 2004-08-12
EP1526845A2 (fr) 2005-05-04
AU2003257982A1 (en) 2004-02-16
AU2003257102A8 (en) 2004-03-29
JP2005538102A (ja) 2005-12-15
EP1526846A2 (fr) 2005-05-04
MXPA05001167A (es) 2005-05-16
MXPA05001166A (es) 2005-05-16
BR0313064A (pt) 2005-06-28
WO2004010974A2 (fr) 2004-02-05

Similar Documents

Publication Publication Date Title
AU2003275620A1 (en) Capsule type hardener and composition
WO2005012356A3 (fr) Gelules de gelatine
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
AP2006003508A0 (en) Method for the preparation of group IB-IIIa_VIA quaternary or higher alloy semiconductor films.
WO2004064762A3 (fr) Nouvelle co-cristallisation
AU2003303458A1 (en) Ampholytic copolymer and use thereof
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AP2004003154A0 (en) Novel perindopril salt and pharmaceutical compositions containing same.
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
EP1636248A4 (fr) Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
WO2003099192A3 (fr) Alcanols bi-aromatiques
WO2005033113A3 (fr) Derives indoles
MXPA03000624A (es) Composiciones y peliculas para la elaboracion de capsulas.
WO2004010974A3 (fr) Capsule de gelatine a reticulation reduite
ZA200309514B (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives.
AU2003251695A1 (en) Novel thiophene derivatives, preparation method thereof and pharmaceutical compositions containing same
WO2005046727A3 (fr) Capsules gelatineuses molles renfermant de l'ibuprofene
AU2003218824A8 (en) Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
WO2004056832A3 (fr) Derives d'epothilone
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
AU2003224482A8 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
HUP0400207A3 (en) Substituted 4-aminocyclohexanol derivatives, process for their preparation and pharmaceutical compositions containing them
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2493980

Country of ref document: CA

Ref document number: 2003772161

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001167

Country of ref document: MX

Ref document number: 2004524263

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003772161

Country of ref document: EP